COMPANYMessage from Our Founder

‘Your partner in nonclinical studies'

Providing our sponsors with the very best in quality and service, our goal is to be a global leader in nonclinical studies.

At Biotoxtech, we are equipped with the latest technology and state-of-the-art facilities. We have submitted hundreds of documents to regulatory agencies around the world, including the US, Europe, and Japan. Biotoxtech has broad and extensive experience, with the highest number of GLP-certified nonclinical studies domestically.

In January 2015, Biotoxtech underwent a GLP inspection by the US FDA becoming the first domestic private nonclinical test facility to have US FDA approval.

In 2008, Biotoxtech was the first such institution in Asia to receive full accreditation, the highest rating from AAALAC International.

In 2010, Biotoxtech was selected as a representative institution for a, OECD MJV (Mutual Joint Visit) GLP inspection.

Furthermore, Biotoxtech is the leader among domestic nonclinical CROs, the first in the country in safety pharmacology and alternatives to animal testing.

Biotoxtech is the only CRO to be listed on KOSDAQ.

In 2011, Biotoxtech, in partnership with Japan’s Sumika Chemical Analysis Service, founded a joint venture in SCAS-BTT Bioanalysis, since renamed KeyFronBio. This company has emerged as the country’s only nonclinical CRO to perform biological sample analyses of synthetic drugs and biopharmaceuticals.

KeyFronBio often works in concert with Biotoxtech and KeyPrime Research to deliver the best possible service to our Sponsors.

We aim to be leaders in our field, endeavoring to provide world-class services to our Sponsors.